We've said before in this blog, that the task of researching and developing new medicines is growing more difficult as the science and technology used in the hunt become more complex. That's why the effort to bring new, collaborative thinking to address scientific and medical challenges, as well as new resources to the work, is so critical to future success.
Most Recent Posts
From the tornadoes that ripped through the Southeast and Central United States to the Japan earthquake and tsunami, the 2011 winter snowstorm and recent flooding along the Mississippi River, Rx Response has been busy tracking potential disruptions to the biopharmaceutical supply system.
This week, the Kaiser Family Foundation released the results of a survey seeking to capture the public's opinions about HIV/AIDS.
Earlier today, the Damon Runyon Cancer Research Foundation launched 'Accelerating Cancer Cures,' a new initiative that brings together PhRMA, some of the industry's leading companies, and partners in academia to address the critical shortage of new young physician-scientists choosing careers in research, while also advancing a translational research model that will play a key role in discovering tomorrow's cancer cures.
Tomorrow, PhRMA and the U.S. Department of Commerce will convene a roundtable discussion on export opportunities for biopharmaceutical research companies, with a particular emphasis on emerging companies as they seek to build an infrastructure that allows for increased exports.
I am pleased to announce that the Virginia Health Care Foundation (VHCF) presented PhRMA with our prestigious You "Rx"ceptional Award for its work with The Pharmacy Connection at our annual "Heroes in Health Care" ceremony on Tuesday, June 14. PhRMA and VHCF have collaborated over the last decade to provide $1 billion worth of free medicine to uninsured Virginians through The Pharmacy Connection.
Throughout the world, chronic non-communicable diseases exert a tremendous economic and social burden. The recent World Health Organization Status Report on Non-communicable Diseases (NCDs) estimates that 63% or 36 million of the 57 million deaths that occurred globally in 2008 were attributable to NCDs , primarily cardiovascular diseases, cancers, diabetes and chronic lung diseases.
Each year, Ernst & Young publishes a report about the global biotechnology sector. In this year's report, which they recently released, they comment about the notable fact that it has been 25 years since they began the report - how far a once-nascent field has evolved in that short amount of time!
It's a hefty read, but they included a really worthwhile two-page chart that details the state of the sector.
An op-ed in the Cleveland Plain Dealer by William Burga, a former president of the Ohio AFL-CIO, is a good reminder that support for patent reform - which I've written about in the past - is important not just to biopharmaceutical research companies, but to all sectors that are stimulated by the patent system.
Summer is finally upon us, and though at times it almost seems too steamy to venture outside, it serves as a good reminder about the importance of taking care of your skin.
Yesterday, PhRMA President and CEO John J. Castellani spoke at the Personalized Medicine Coalition's 7th annual State of Personalized Medicine Luncheon. He spoke about the many challenges confronting the biopharmaceutical sector as it increasingly turns its attention to personalized medicine, but also about the promise that the field offers.